Adult stem cells are a viable treatment option for patients suffering from peripheral neuropathy. The stem cells are harvested from a person’s umbilical cord and reprogrammed for use as a treatment for peripheral neuropathy. This treatment can provide relief from the symptoms of neuropathy and can help patients get back to living a peripheral neuropathy stem cell, pain-free life. This treatment is suitable for individuals with all types of neuropathy, including those with autoimmune diseases.
Adult stem cells are injected directly into the affected areas of the peripheral nervous system, about a centimeter deep, one cell for every two nerves. These cells have been found to improve the condition of patients with delayed nerve repair and chronic denervation. But the mechanisms behind the paracrine effect of adult stem cells are still unknown. While the potential benefits of this treatment are significant, a number of questions remain. Further research is needed to fully understand the mechanism of the paracrine effect.
Traditional medical approaches are ineffective for patients with peripheral neuropathy. However, some treatments are effective for pain relief and numbness, while other treatments may not. Medications may not be able to address the underlying cause of peripheral neuropathy. Some treatments may involve undergoing a clinical trial or an institutional trial. It is imperative to thoroughly research any provider before proceeding. Although conventional medical treatments are the mainstay of treatment, they may have side effects or have insufficient effectiveness.
Stem cells are capable of inhibiting central:
For patients with autoimmune neuropathy, a stem cell transplant may be the right choice. Patients undergo a stem cell treatment for peripheral neuropathy after a thorough medical history and physical examination. After the treatment, stem cells go to work directly on the affected nerves. In addition to neuropathy, patients suffering from cancer treatments may also suffer from chemo or diabetic neuropathy. The transplanted stem cells can help the patient live a better life.
While experimental studies have shown that stem cells are capable of inhibiting central sensitization, more research is needed to understand how these cells interact with the brain to treat it. A recent study from Teng et al. demonstrated that intrathecal injection of siRNA-treated BMSCs reduced the number of injured DRG-derived stem cells. Furthermore, treatment duration may influence the outcome of the stem cells. Further research should be conducted to better understand the mechanisms involved between the glial cells and stem cells in peripheral neuropathy.
While there are still risks associated with stem cell treatment, they are low compared to the risks of conventional therapies. Injection of the stromal vascular fraction has shown efficacy in treating Parkinson’s disease. The stromal vascular fraction is particularly effective in treating autism, which is characterized by a variegated auto immune system. While autologous stem cell treatments may not be practical, a similar treatment using umbilical cord stem cells has shown promising results.
Treatment of peripheral neuropathy:
Diabetic patients may be candidates for the treatment of peripheral neuropathy. In addition to the neuropathy associated with diabetes, MSCs have anti-inflammatory properties that could help diabetic patients. The treatment has also been shown to reduce inflammation and modulate the immune system. In the future, patients with mesenchymal peripheral neuropathy will be the main subjects of stem cell research. This new technique may ultimately improve the quality of life for patients with mesenchymal neuropathy.
There are several types of peripheral neuropathy. About 25% of cases are idiopathic. These are conditions that are cause by a number of factors, such as exposure to toxins and repeat vibrations. These patients may have degenerative neuropathy, and medications and stem cell therapy may help alleviate the painful symptoms. In addition to being effective in treating the symptoms, these treatments may also improve motor function and other aspects of the patient’s life.
Although there are a number of unknowns about this treatment, small patient studies suggest promising results. A recent study of MSC transplantation in patients with neurotrigeminal neuralgia reported reduced pain scores in five out of nine patients after six months. These results are encouraging for the future of stem cell treatment for peripheral neuropathy. If successful, they could even be used as a treatment for other neuropathies. Once these studies are complete, more research will be need to determine whether this treatment is a viable option.